FORMYCON AG (FYB)

Sell: €23.65|Buy: €24.10|Change: 0.15 (-0.63%)

Open

€23.75

Previous close

€23.85

Trade high

€24.25

Volume

78,398

Year high

€64.40

Year low

€19.02

Dividend yield

–

Market capitalisation

€418.65 mn

P/E ratio

5.77

ISIN

DE000A1EWVY8

This share can be held in a Dealing account

Share price

Performance 19/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
FORMYCON AG	- 0.63
More...

Company profile

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.